was successfully added to your cart.

Mitigating the Dangers of Statin Myopathy with PGx Testing

By January 17, 2017PGx in the News
  • Statins are the most commonly prescribed drugs in the United States and are extremely effective in reducing major cardiovascular events in the millions of Americans with hyperlipidemia, according to recent research in Journal of Pharmacogenomics and Pharmacoproteonomics: “Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants,” Talameh and, Kitzmiller (2014)


    Unfortunately, 25-60% of all users cannot tolerate or discontinue statin therapy due to statin-induced myopathy (SIM), and “[p]atients will continue to experience SIM at unacceptably high rates or experience unnecessary cardiovascular events (as a result of discontinuing or decreasing their statin therapy) until strategies for predicting or mitigating SIM are identified,” according to the research.


    A promising strategy for predicting or mitigating SIM is pharmacogenetic testing, particularly of pharmacokinetic genetic variants as SIM is related to statin exposure, the investigators stated, noting that research investments in pharmacokinetic genetic variants have the potential to make a profound impact on public health.” Future directions, specific to the research on pharmacokinetic genetic variants, could speed the translation into clinical practice.








    Related Post

  • Leave a Reply